Jubilant Pharmova has announced physical investor and analyst meetings scheduled for February 09, 2026 in Mumbai, as disclosed in a regulatory filing under Regulation 30 of SEBI's Listing Obligations and Disclosure Requirements Regulations, 2015. The pharmaceutical company will conduct one-on-one and group meetings with institutional investors to discuss its Q3FY26 earnings performance.

Meeting Details and Organization

The investor meetings are being organized by Nuvama Institutional Equities as part of their Nuvama India Conference 2026. The company has indicated that the schedule may undergo changes due to exigencies on the part of investors, analysts, or the company itself. These physical meetings represent a significant engagement opportunity between Jubilant Pharmova's management and key institutional stakeholders.

Participating Institutional Investors

A total of 29 institutional investors are scheduled to participate in the meetings, representing a diverse mix of domestic and international investment entities:

Other notable participants include Ambit Asset Management, Bay Capital Advisors, Equentis Advisors, IIFL PMS, JM Family Office, NV Alpha FM, Purnartha Investment Advisors, Sameeksha Capital, Shravas Capital Advisors, Subhkam Ventures, Sundaram Alternate Assets, and various mutual funds including ITI MF, Trust MF, and Union MF.

Earnings Discussion Focus

The primary agenda for these meetings will be the discussion of Jubilant Pharmova's Q3FY26 earnings presentation. The company has specified that this earnings presentation will be filed on February 6, 2026, following the disclosure of Q3FY26 financial results. This timeline indicates that investors will have access to the complete financial data before the physical meetings, allowing for detailed discussions and clarifications.

Regulatory Compliance

The announcement demonstrates Jubilant Pharmova's commitment to regulatory compliance and transparent investor communication. By providing advance notice of these meetings under Regulation 30, the company ensures proper disclosure to all stakeholders and maintains market transparency standards required by SEBI regulations.

Jubilant Pharmova Limited has informed stock exchanges about receiving a significant tax demand order from the Income Tax Department. The pharmaceutical company disclosed this development under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

Tax Demand Details

The Income Tax Department, DCIT/ACIT (Central), Moradabad, has raised a tax demand of ₹22.10 crores against Jubilant Pharmova for the financial year 2020. The order was dated December 27, 2025, with the company receiving it on December 30, 2025, at 4:23 PM (IST).

Basis of Tax Demand

The tax demand primarily arises from several issues identified by the Income Tax Department:

• Arithmetical errors and mistakes apparent from records
• Disallowances of expenses and deductions
• Transfer pricing adjustments
• Ignoring the contentions presented by the company

Company's Response Strategy

Jubilant Pharmova has expressed strong disagreement with the tax demand, stating that it suffers from mistakes apparent from records and was made while ignoring the company's contentions. The company has outlined its response strategy to challenge the order.

Management Outlook

The company maintains confidence in its position, believing that the impugned tax demand will likely be deleted post the redressal process. Jubilant Pharmova does not anticipate any material financial implications from this matter, indicating management's confidence in successfully challenging the order through appropriate legal channels.

The disclosure was made by Company Secretary Naresh Kapoor on December 31, 2025, ensuring compliance with regulatory requirements and keeping stakeholders informed about this significant development.